Skip to main navigation Skip to search Skip to main content

Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

  • So Hee Hong
  • , Hanseul Oh
  • , Yong Wook Park
  • , Hye Won Kwak
  • , Eun Young Oh
  • , Hyo Jung Park
  • , Kyung Won Kang
  • , Green Kim
  • , Bon Sang Koo
  • , Eun Ha Hwang
  • , Seung Ho Baek
  • , Hyeong Jun Park
  • , Yu Sun Lee
  • , Yoo Jin Bang
  • , Jae Yong Kim
  • , Seo Hyeon Bae
  • , Su Jeen Lee
  • , Ki Weon Seo
  • , Hak Kim
  • , Taewoo Kwon
  • Ji Hwan Kim, Seonghwan Lee, Eunsom Kim, Yeonhwa Kim, Jae Hak Park, Sang In Park, Marta Gonçalves, Byung Mook Weon, Haengdueng Jeong, Ki Taek Nam, Kyung Ah Hwang, Jihye Kim, Hun Kim, Sang Myeong Lee, Jung Joo Hong, Jae Hwan Nam
  • The Catholic University of Korea
  • Korea Research Institute of Bioscience and Biotechnology
  • SK Bioscience
  • Jeonbuk National University
  • Chungbuk National University
  • Seoul National University
  • Scripps Korea Antibody Institute
  • Sungkyunkwan University
  • Yonsei University
  • SML Genetree
  • Kyung Hee University

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), various vaccines are being developed, with most vaccine candidates focusing on the viral spike protein. Here, we developed a previously unknown subunit vaccine comprising the receptor binding domain (RBD) of the spike protein fused with the tetanus toxoid epitope P2 (RBD-P2) and tested its efficacy in rodents and nonhuman primates (NHPs). We also investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy. Immunization with N and RBD-P2 (RBDP2/N) + alum increased T cell responses in mice and neutralizing antibody levels in rats compared with those obtained using RBD-P2 + alum. Furthermore, in NHPs, RBD-P2/N + alum induced slightly faster SARS-CoV-2 clearance than that induced by RBD-P2 + alum, albeit without statistical significance. Our study supports further development of RBD-P2 as a vaccine candidate against SARS-CoV-2. Also, it provides insights regarding the use of N in protein-based vaccines against SARS-CoV-2.

Original languageEnglish
Article numbereabg7156
JournalScience advances
Volume7
Issue number22
DOIs
StatePublished - May 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates'. Together they form a unique fingerprint.

Cite this